Authors' recommendations: Alogliptin (Vipidia®) is recommended as an option for restricted use for dual oral therapy within NHS Wales. Alogliptin (Vipidia®) should be restricted for use in the following circumstances within its licensed indication for the treatment of adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control: • In combination with metformin (dual therapy), when metformin alone, together with diet and exercise does not provide adequate glycaemic control in patients for whom the addition of a sulphonylurea is inappropriate; • In combination with a sulphonylurea (dual therapy), when a sulphonylurea alone, together with diet and exercise does not provide adequate glycaemic control in patients for whom the addition of metformin is inappropriate. Alogliptin (Vipidia®) is not recommended for use within NHS Wales outside of these circumstances.

Project Status: Completed

Year Published: 2014

URL for published report: http://www.awmsg.org/awmsgonline/app/appraisalinfo/857

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Wales, United Kingdom

Organisation Name: All Wales Medicines Strategy Group

Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX

Contact Name: AWTTC@wales.nhs.uk

Contact Email: AWTTC@wales.nhs.uk

Copyright: AWTTC